Ultra-sensitive urine-based test for the surveillance of low, intermediate and high-risk non-muscle-invasive bladder cancer (NMIBC)
Reduces follow-up cystoscopies
Replaces urine cytology
- URODIAG uses its own diagnostic algorithm that identifies the presence or absence of the bladder cancer
EP 13306580, 2013: Methods for the surveillance, diagnosis and screening of bladder cancer. November 18, 2014: International extension extension PCT/EP2014/074892. May 19, 2016: Entering national phase (EU, US, CA, AU, JP)
Roperch JP and Hennion C. A novel ultra-sensitive method for the detection of FGFR3 mutations in urine of bladder cancer patients - Design of the Urodiag PCR kit for surveillance of patients with non-muscle-invasive bladder cancer (NMIBC). BMC Medical Genetics. 2020 May 24;21(1)112.
Roperch JP, et al; Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer. BMC Cancer. 2016 Sep 1;16:704.